Desmoteplase

Expert Opinion on Biological Therapy

Volumn 9, Issue 6, 2009, Pages 773-778

  Paciaroni, Maurizio ^a   Medeiros, Elisabeth ^b   Bogousslavsky, Julien ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c Swiss Medical Network   (Switzerland)

Author keywords

Acute stroke; Desmoteplase; Therapy; Thrombolysis

Indexed keywords

DESMODUS ROTUNDUS SALIVARY PLASMINOGEN ACTIVATOR ALPHA1; DESMODUS ROTUNDUS SALIVARY PLASMINOGEN ACTIVATOR ALPHA2; DESMODUS ROTUNDUS SALIVARY PLASMINOGEN ACTIVATOR BETA; DESMODUS ROTUNDUS SALIVARY PLASMINOGEN ACTIVATOR GAMMA; DESMOTEPLASE; HEPARIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY THROMBOSIS; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ECHO PLANAR IMAGING; HEART INFARCTION; HUMAN; LUNG EMBOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; STENOSIS;

CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; STROKE;

DESMODUS ROTUNDUS;

EID: 67649133145     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902991497     Document Type: Article

References (32)

1. Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother 2007;7:333-337 (Pubitemid 46623356)
2. Douglas VC, Tong DC, Gillum LA, et al. Do the brain attack Coalition's criteria for stroke centers improve care for ischemic stroke? Neurology 2005;64:422-427
3. The National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329
5. Arnold AE, Brower RW, Collen D, et al. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. J Am Coll Cardiol 1989;14:581-588 (Pubitemid 19229330)
6. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270:25596-25603
7. Kratzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus, cloning and expression. Gene 1991;105:229-237
8. Hawkey C. Plasminogen activator in the saliva of the vampire bat Desmodus rotundus. Nature 1966;211:434-435
9. Schleuning WD, Alagon A, Boidol W, et al. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci 1992;667:395-403 (Pubitemid 23061605)
10. Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-426
11. Schleuning WD. Vampire bat plasminogen activator DSPA-alpha-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001;31:118-122 (Pubitemid 34702043)
12. Petri T, Langer G, Bringmann P, et al. Production of vampire bat plasminogen activator DSPAα1 in CHO and insect cells. J Biotechnol 1995;39:75-83
13. Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998;273:18292-18299 (Pubitemid 28334753)
14. Walker JB, Nesheim ME. A kinetic analysis of the tissue plasminogen activator and DSPAα1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J Biol Chem 2001;276:3138-3148 (Pubitemid 37411605)
15. Renatus M, Stubbs MT, Huber R, et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997;36:13483-13493 (Pubitemid 27481594)
16. Pugsley MK, Lipka L, Petersen KU, Soehngen M. A new hope for stroke? Evidence for the use of rDSPAα1 (Desmoteplase) in acute ischemic stroke. Proc West Pharmacol Soc 2006;49:1-5 (Pubitemid 46657549)
17. Epple G, Schleuning WD, Kettelgerdes G, et al. Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2. J Thromb Haemost 2004;2:962-968 (Pubitemid 40185744)
18. Lopez-Atalaya JP, Roussel BD, Ali C, et al. Recombinant desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007;38:1036-1043 (Pubitemid 46568471)
19. Tsirka S, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996;384:123-124 (Pubitemid 26386459)
20. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (Desmoteplase). A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-543
21. Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (Desmoteplase) inhibits tissue-type plasminogen activity-induced potential of excitotoxic injury. Stroke 2005;36:1241-1246 (Pubitemid 40798746)
22. Tebbe U, Bramlage P, Graf A, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009;101:557-562
23. Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a Phase II MRI-based 9-hours window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73 (Pubitemid 40054177)
24. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231 (Pubitemid 43731867)
25. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-150
26. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-1251 (Pubitemid 28470336)
27. DIAS-3. Efficacy and safety study of Desmoteplase to treat acute ischemic stroke. The Internet Stroke Center, Stroke Trials Registry, 2009. Available from: http://www.strokecenter.org/trials/trialDetail.aspx?tid=914&search- string=DIAS [Last accessed 26 April 2009]
28. DIAS-4. Efficacy and Safety study of desmoteplase to treat acute ischemic stroke The Internet Stroke Center, Stroke Trials Registry, 2009. Available from: http://www.strokecenter.org/trials/trialDetail.aspx?tid=961&search- string=DIAS [Last accessed 26 April 2009]
29. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517 (Pubitemid 44871793)
30. Davis SM, Donnan GA, Persons MW, et al. Effects of alteplase beyond 3 h stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol 2008;7:299-309
31. Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311-321 (Pubitemid 19170247)
32. Donnan GA, Baron JC, Davis S. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009;8:261-269